share on google plus
Text size
view with small font size
view with medium font size
view with large font size


Moventig® is indicated for the treatment of opioid induced constipation (OIC) in adult patients who have had an inadequate response to laxatives. It is the first oral once daily peripherally acting mu-opioid receptor antagonist (PAMORA) that selectively blocks mu-opioid receptors in the bowel, providing patients relief from opioid induced constipation (OIC) without impacting their pain control.

moventig® naloxegol

Marketed by Kyowa Kirin International in

Worldwide Locations

To Page Top